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A B S T R A C T

Coronavirus disease-19 (COVID-19) pandemic is associated with high morbidity and mortality. COVID-19, which is caused by the Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS CoV-2), affects multiple organ systems through a myriad of mechanisms. Afflicted patients present with a vast constellation of symptoms, from
asymptomatic disease to life-threatening complications. The most common manifestations pertain to mild pulmonary symptoms, which can progress to respiratory
distress syndrome and venous thromboembolism. However, in patients with renal failure, life-threatening cardiac abnormalities can ensue. Various mechanisms such
as viral entry through Angiotensin receptor (ACE) affecting multiple organs and thus releasing pro-inflammatory markers have been postulated. Nevertheless, the
predictors of various presentations in the affected population remain elusive. An ameliorated understanding of the pathology and pathogenesis of the viral infection
has led to the development of variable treatment options, with many more that are presently under trial. This review article discusses the pathogenesis of multiple
organ involvement secondary to COVID-19 infection in infected patients.

1. Introduction
The Coronavirus disease pandemic (COVID-19) caused by Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) has affected
over 185 countries with a reported total number of 2,790,986 cases and
195,920 deaths [1]. The United States is one among the countries
leading in COVID-19 associated infections and death rates [2]. The
symptomatology associated with COVID-19 is variable from asymp
tomatic cases to multiorgan dysfunction and death [3]. Due to severe
systemic inflammatory response from cytokine release, COVID-19 leads
to end-organ damage and multiorgan failure (MOF) [3,4]. Understand
ing the underlying pathophysiology of COVID-19 for each organ system

is critical for developing new therapies and improving management. We
aim to do a systematic review of the literature to understand the path
ophysiology of multiorgan involvement.
1.1. Multiorgan failure secondary to COVID-19
The multiorgan failure associated with COVID-19 is secondary to
severe systemic inflammatory syndrome [3,4]. Studies have shown a
strong association between ACE receptor and COVID-19 induced severe
inflammatory response [5]. TMPRSS-2 is a serine protease involved in
receptor-mediated endocytosis of SARS-CoV-2 [6–8]. The binding of
SARS-CoV-2 virus results in the downregulation of ACE2 receptors,
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which means that angiotensin II levels begin to elevate. This elevation
leads to a plethora of downstream effects on cytokine signaling, vascular
homeostasis, and the coagulation cascade [5]. Cytokine storms can
manifest as lymphopenia and elevated serum markers of inflammation
including D-dimer, IL-6, ferritin and C-reactive protein (CRP) that can
lead to multi organ failure [9].

PAI-1 expression, the sequestration of platelets, and hypoxemia
releasing a variety of hypoxia-inducible factors (HIF-1) add fuel to the
impaired state [22–24]. High D-dimers observed in COVID-19 are
representative of this dysfunctional coagulation activity requiring fibrin
breakdown (Fig. 1).
1.2.2. COVID and pulmonary disease
COVID-19 infection is associated with acute respiratory distress
syndrome from severe inflammatory response [16]. Burst of proin
flammatory cytokines initiate alveolar injury, pulmonary edema, and
reduced oxygenation within pulmonary vessels. This hypoxic state leads
to pulmonary vasoconstriction, increased vascular permeability with an
influx of inflammatory cells within the lung parenchyma, thereby
reducing surfactant levels and atelectasis. A right-to-left shunt ensues a
ventilation/perfusion mismatch with an increased physiological dead
space [25–27]. As a result of hypoxic lung injury, viral replication fol
lows unopposed activation of Angiotensin II [28].
The elevations in Ang II and decreased ACE II expression post viral
entry contribute to generation of reactive oxygen species through nu
clear factor kappa light chain (NFkB) activation [24] (Fig. 2). The
expression of inflammatory genes further lead to generation of proin
flammatory cytokines like tumor necrosis factor alpha (TNF-alpha),
interleukin-1 (IL-1), and IL-6. The cytokine surge contributes to endo
thelial dysfunction via uncoupled nitrous oxide (eNOS), increased
endothelin-1(ET-1) levels, reactive thrombocytosis, and formation of
emboli which lodge into pulmonary vessels causing acute hypoxic
changes [29,30]. Oxygen deficient states also cause activation of hyp
oxia inducible factors (HIF1-alpha, enacting angiogenesis, elevated
levels of fibrinogen, and consumption of clotting factors. Further, levels
of PAL-1 lead to reduced depletion of fibrin causing perfusion deficiency
and pulmonary dysfunction [4,31].

1.2. Acute respiratory distress syndrome
Angiotensin-converting enzyme 2 (ACE2) receptor facilitate SARSCoV-2 cell entry by providing a direct binding site for the S proteins of
SARS-CoV-2 and promotes cleavage of angiotensin (Ang) I to produce
Ang-(1–9) [10]. ACE2 receptors are widely expressed in the human body
such as in nasal mucosa, bronchus, lung, heart, esophagus, kidney,
stomach, bladder, and ileum which are all potential targets for COVID19
[11]. Once the virus enters, it induces ACE2 downregulation and shed
ding [10]. This is the primary mode of entry for SARS-COV2 and affects
different organ systems. The ACE2 receptor expressed in the human
airway epithelium is converted to active soluble ACE2 (sACE2) by dis
integrin and metalloprotease 17.
Downregulation of ACE2 receptors is compensated by over
production of angiotensin II (Ang II) by ACE which stimulates angio
tensin II type 1a receptor that increases lung vascular permeability
leading to acute lung injury and induces acute respiratory distress syn
drome (ARDS) function [8]. Lung tissue has high RAS activity, enhanced
during hypoxic state, and is the leading site of Ang II synthesis. Ang II is
a pulmonary vasoconstrictor, resulting in pulmonary hypertension [5],
and can also promote the occurrence of pulmonary edema and impair
lung function [8].
In response to viral entry, the innate and adaptive immune system
response secrete cytokines and inflammatory markers (see coagulopathy
section) to combat the virus, specifically, increased production of cy
tokines interleukin-6 (IL-6), early induction of CXCL10, interleukin-2
(IL-2) and decreased production or absence of interleukin-10 (IL-10)
which in turn promotes acute lung injury [12]. The viral overload and
delayed type I interferon signaling further precipitate lung injury by
accumulation of monocyte/macrophages that release cytokine/chemo
kine in the extracellular matrix and further attract accumulation of in
flammatory cells induced inflammatory response and cell injury [12].
Excessive neutrophil can induce lung injury and CD8, cytotoxic T cells,
contribute to lung damage from cytokines [12].

1.3. Acute kidney injury
The mechanisms involved in heralding the onset of acute kidney
injury (AKI) remain elusive, but a concoction of factors, such as hemo
dynamic changes, fluid overload, right heart failure, and cytokinestorm, might be at play in eliciting AKI [13]. The mechanistic features
underlying AKI are therefore the subject of extensive medical research,
and we hereby detail a schematic representation of the etiology under
lying AKI.
Cytokines produced as part of a SARS-CoV-2 response, such as IL-6,
upregulates the expression of sodium hydrogen exchangers. As a result,
the adenosine triphosphatase (ATPase) molecules undergo hypertrophy.
Complementing this tubular ATPase hypertrophy is hypoxia, which
routinely results as a ramification of ARDS [25]. The hypoxia results in
increased aldosterone retention, which consequently increases water
retention, worsening renal failure. It is imperative to note, also, that AKI
portends worse outcomes if it is superimposed on an existing chronic
kidney disease (CKD) [13]. Increased acid secretion levels eventually
lead to increased intraglomerular pressure, thereby damaging the
filtration barrier. To compensate, tubular fibroblasts release mediators,
such as NFKB and ETS-1, which culminate in tubular atrophy, inflam
mation, and fibrosis) [13]. The summary for mechanisms of AKI is
shown in Fig. 3.

1.2.1. SARS-CoV-2 coagulopathy and thromboembolism
COVID-19 induced coagulopathy has been reported in many case
reports ranging from immune thrombocytopenic purpura, deep venous
thrombosis, carotid artery thrombus, pulmonary embolism, and
disseminated intravascular coagulation (DIC) [10,13–16]. Severe
COVID-19 infection was associated with a more procoagulant state with
higher rates of pulmonary embolism [9]. However, a meta-analysis by
Mir et al. did not reveal any worsening in mortality in such critically ill
patients with pulmonary embolism [17] The procoagulant state of
COVID-19 infection is related with the inflammatory response of cyto
kines and tissue injury. Proteins expressed via SARS-CoV-2 virus likely
delay the Type 1 IFN (interferon) release allowing fast viral replication,
thus a dysregulated release of IFN-1 emerges [7]. As a result, proin
flammatory cytokines, for example IL-6 and TNF-alpha stimulate neu
trophils (PMNs) and monocytes thereby inciting a hyperinflammatory
response, vascular leakage, and endothelial dysfunction [7]. Activated
endothelial cells stimulate tissue factors and the extrinsic pathway
whereas activated PMNs secrete neutrophil extracellular traps (NETs),
which contain DAMPs that lead to activation of the intrinsic pathway via
factor II. Further, combined activation of the intrinsic and extrinsic
pathway coupled with reduced plasminogen activator inhibitor-1
(PAI-1) levels in ARDS resulting widespread thrombosis, a story simi
larly seen in the previous SARS-CoV-1 induced thrombosis [18–21]. In
addition, the upregulation of the Ang II-AT-1R axis, which promotes

1.3.1. Cardiovascular complications: heart failure, STEMI, arrhythmias,
and cardiac tamponade
COVID-19 can cause cardiac complications such as myocarditis.
Clinically, patients might present with chest pain, dyspnea, arrhythmias,
and acute coronary syndrome (ACS) [17]. Distinguishing between ACS
and myocarditis in an acute setting might be challenging. A proposed
mechanism that explains myocarditis is elucidated. In addition to the
mentioned cardiovascular side effects, SARS-CoV-2 also causes heart
failure, pericarditis, cardiac tamponade, arrhythmias and thromboem
bolic events. It is presently understood that electrolyte disturbances,
2
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Fig. 1. Pathogenesis of the procoagulant state secondary to COVID-19.

TMPRSS serine proteases facilitate virus infection by inducing S cleav
age and exposing the fusion peptide for efficient viral entry in gastro
intestinal (GI) tract [35] Inflammatory response induced by SARS-CoV-2
can also lead to direct injury of GI tract, destroying absorptive enter
ocytes, potentially leading to malabsorption, unbalanced intestinal
secretion, and enteric nervous system [34,58]. Additionally, hyper
inflammation and dysregulated immune responses lead to cytokine
surge which may culminate in widespread injury and serious compli
cations like paralytic ileus and hemorrhagic colitis [22,36].

coupled oxidation of the Ca2+/Calmodulin-dependent protein kinase 2
is responsible for the arrhythmias seen amid a SARS-CoV-2 infection
[26].
Similarly, the exorbitant increase in the production of IL-6 upregu
lates the expression of vascular endothelial growth factor (VEGF)
resulting in increased vessel permeability and effusion that may progress
to cardiac tamponade [32]. Additionally, due to deranged coagulation
profiles and increased circulating levels of angiotensin II, downstream
pathways involving endothelial dysfunction and oxidative stress herald
the onset of thromboembolic events [3].
The stimulation of these pathways lead to increased production of
mononuclear infiltrates, which are directed towards the myocardium,
and might result in subsequent myocarditis [33]. The elevated troponin
levels among patients with COVID-19 might be a result of demand
ischemia rather than myocarditis itself [11]). It is therefore of clinical
relevance that the troponin levels are not used exclusively, but instead in
conjunction with the overall clinical picture, to yield a diagnosis of
myocarditis. The graphic representation of cardiovascular pathology is
in Fig. 4.
Both above detailed pathways lead to increased production of
mononuclear infiltrates, which are directed towards the myocardium,
leading to myocarditis [33]. Fig. 5. In study by Deng et al. troponemia in
myocarditis suspect can be a demand for ischemia in the setting of
COVID-19 rather than myocarditis itself [11]. It is therefore of clinical
relevance that the troponin levels are not used exclusively, but instead in
conjunction with the overall clinical picture, to yield a diagnosis of
myocarditis.

1.4.1. Neurologic manifestation
Significant neurologic complications such as increased risk for
ischemic and hemorrhagic stroke have become increasingly associated
with COVID-19. There are many case reports and observational studies
demonstrating that these patients presented with stroke often in the
early stages of their illness [37,38]. Cytokine release induced hyperco
agulability (as evidenced by remarkable D-Dimer elevation) contributes
to significant downstream thrombus formation. Hypoxemia leading to
intracellular acidosis and down-stream production of oxygen free radi
cals, compounded by the influx of proinflammatory cytokines, may lead
to neuronal tissue ischemia. It is known that inflammation contributes
significantly to atherosclerosis and increases the instability of plaques,
predisposing to stroke [39].
When SARS-CoV-2 binds with ACE II receptors, patients with un
derlying hypertension may additionally be affected by extremes of high
blood pressure, putting them at risk for intracerebral hemorrhage. Some
patient cohorts have also been shown to present with thrombocytopenia,
further increasing risk of intracerebral bleeding [40].
Inflammatory response and cytokine storm can affect the central
nervous system by inducing toxic metabolic encephalopathy. In one
confirmed case, a patient presented with fever and cough, which later
progressed to acute necrotizing encephalopathy related to the cytokine
storm [38]. There are also case reports of meningitis, confirmed by
detection of the virus within the CSF, and hippocampal sclerosis leading
to post-convulsive encephalopathy from COVID-19 [41] (Fig. 6).
SARS-CoV-2 binding to ACE-2 Receptors followed by viral endocy
tosis causes upregulation of Ang II/AT-1R; this results in endothelial
dysfunction which includes vasoconstriction and increased shear stress.
Endothelial dysfunction leads to cytokine release, including Il-1, Il-6 and
TNF-alpha, culminating in increased blood brain barrier permeability.
This increased inflammatory cytokine activity leads to hypercoagula
bility. The hypercoagulable state leading to stroke compounded by
ARDS hypoxemia leads to downstream neuronal ischemia, inflamma
tion, and necrosis secondary to reperfusion injury [42–47]. Ang-II/AT1R
upregulation related enzymatic activity within both glial cells and
neurons, in addition to ischemia and reperfusion injury, leads to reactive
oxygen species production, stimulation of proteases, with cell and

1.4. Gastrointestinal
The colon and small intestine have higher expression of ACE2 re
ceptors mainly in the endothelium and the vascular smooth muscle cells
[34]. SARS-CoV-2 is associated with infiltration of plasma cells and
lymphocytes in the lamina propria of stomach, duodenum and rectum
that promotes interstitial edema. ACE2 receptor is also associated with
neutral amino acid transporters in the gastrointestinal tract and plays an
essential role. In patients with amino acid malnutrition, ACE2 promotes
intestinal inflammation. ACE2 plays a significant role in amino acid
homeostasis and maintaining intestinal microbiota [34]. Down
regulation or alteration of ACE2 is associated with colitis, by promoting
intestinal inflammation and diarrhea suggesting that SARS-Co-2 entry
via ACE2 receptor may alter its activity. The proposed model is that
COVID19 uses ACE2 and TMPRSS22 to enter the gut [35].
The entry of SARS-CoV-2 into the host cell begins by the binding of
viral spike glycoprotein with ACE2 protein followed by processing of the
spike glycoprotein by TMPRSS2 leading to membrane fusion, and recent
evidence suggests an additive effect of TMPRSS4 in viral entry [35].
3
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Fig. 2. The mechanisms underlying SARS-CoV-2 induced ARDS [1] a hypothetical model of SARCoV-2 virus demonstrating infectious pathways to cell entery,
induce inflammation, ARDS and procoagulation state. SARS CoV-2; Severe Acute Respiratory Syndrome Coronavirus-2, IL-6; Interleukin − 6, TNFα; Tumor necrosis
alpha, IL 1-β; Interleukin 1-beta, ACE II; Angiotensin converting enzyme II, Ang II; Angiotensin II (Created with BioRender.com).

membrane damage as a result [48–52]. Apoptosis of neurons occurs
because of DAMP release from cell membrane damage, ATP depletion,
and mitochondrial damage [53–55,57,58].
The downstream effects of this neuro-inflammatory process and
excitotoxicity may manifest as altered mental status including psychosis
and exacerbation of existing dementia.

exact contribution of risk factors to disease progression in different age,
sex and race groups. Additionally, more studies are needed to under
stand the main drivers of COVID-19 and their molecular mechanisms of
action especially in different age groups, which would help for appro
priate risk stratification and therapeutic strategies. From our under
standing of the published studies and evidence, immunomodulatory
therapies are more likely to be equally and also very effective than just
targeting virus at different stages of cycle in humans. Furthermore,
treatment approaches may be further tailored to support immune
response earlier during disease progression to enhance an efficient
antiviral response and also to prevent progression of the disease into
multi system inflammatory syndrome.

1.5. Future directions
This review gives a potential pathophysiological mechanism behind
SARS-CoV-2 infection for every system that it involves. The evidence
behind these mechanisms is based on experience with similar corona
viruses and other viral infections of the same class, as well as clinical
characteristics, laboratory findings, and postmortem pathological re
ports of COVID-19 patients around the world. The main concern is the
4
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Fig. 3. Pathogenesis underlying the acute kidney injury (AKI) seen in SARS-CoV-2. SARS CoV-2; Severe Acute Respiratory Syndrome Coronavirus-2, IL-6; Interleukin
− 6, TNFα; Tumor necrosis alpha, IL 1-β; Interleukin 1-beta, ACE II; Angiotensin converting enzyme II, Ang II; Angiotensin II (Created with BioRender.com).

Fig. 4. Cardiovascular pathology of COVID-19. SARS CoV-2; Severe Acute Respiratory Syndrome Coronavirus-2STEMI; ST-elevation myocardial Infarction, NSTEMI;
Non-ST elevation myocardial infarction (Created with BioRender.com).
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Fig. 5. Pathogenesis of myocarditis in COVID-19 infection.

Fig. 6. Neurologic involvement in COVID-19.

2. Conclusion

Ethical approval

COVID-19 has been related as a respiratory illness, however through
our extensive review of systems it can now be considered as a complex
multisystem disorder. Moreover, there is a need to better understand the
varied presentation of symptoms and organ involvement in different
populations, nevertheless with the emerging epidemiology and basic
science evidence, there has been some understanding of susceptibility of
the infection and its outcomes. Even with initiation of mass vaccination
drive of COVID vaccines the SARS-CoV-2 infection is expected to
continue to be a burden to the healthcare sector and also to the country’s
economy. Hence there is need for more prospective studies to better
understand this disease and varied involvements of the organs in
different patients so that an effective therapy can be directed.

Research studies involving patients require ethical approval. Please
state whether approval has been given, name the relevant ethics com
mittee and the state the reference number for their judgement.
NA.
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